At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 13 Jun 1995 Development has been discontinued
- 13 Jun 1995 Discontinued-Preclinical for HIV-1 infections in USA (Unknown route)
- 11 Oct 1994 No-Development-Reported for HIV-1 infections in USA (Unknown route)